Physician Concerns with United States Drug Enforcement Agency Schedule II Central Nervous System Stimulants

Primary Psychiatry

Volumn 10, Issue 2, 2003, Pages 47-52

  Hellerstein, David J ^a   Biedermann, Gregory B ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; ANTIDIARRHEAL AGENT; BARBITURIC ACID DERIVATIVE; CENTRAL STIMULANT AGENT; CODEINE; DEXAMPHETAMINE; DIAMORPHINE; LYSERGIDE; METHYLPHENIDATE; NARCOTIC ANALGESIC AGENT; PEMOLINE; SEDATIVE AGENT;

ATTENTION DEFICIT DISORDER; DRUG DEPENDENCE; FATIGUE; GENERAL PRACTICE; HEALTH SURVEY; HUMAN; MEDICAL PRACTICE; NARCOLEPSY; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; SLEEP APNEA SYNDROME; TOXICITY; TREATMENT INDICATION; UNITED STATES;

EID: 1842505400     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Koob GF. Stimulants: basic mechanisms and pharmacology In: Kryger MH, Roth R, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders Co; 2000:419-428.
2. Ritalin [package insert]. Novartis: East Hanover, NJ; 1999.
3. Cylert. [package insert]. Medical Economics Company, Inc.; 1999.
4. Dexedrine. [package insert]. Medical Economics Company, Inc.; 1999.
5. Adderall. [package insert].Shire Richwood, Inc.; 1998.
6. Provigil. [package insert].CePhalon, Inc; 2000.
7. Dackis CA, Gold MS. Addictiveness of central stimulants. Adv Alcohol Subst Abuse. 1990;9:9-26.
8. Wise RA, Bozarth MA. Brain mechanisms of drug reward and euphoria. Psychiatr Med. 1985;3:445-460.
9. Parran TV Jr, Jasinski DR. Intravenous methylphenidate abuse. Prototype for prescription drug abuse. Arch Intern Med. 1991;151:781-783.
10. Spier SA. Toxicity and abuse of prescribed stimulants. Int J Psychiatry Med. 1995;25:69-79.
11. Fernandez F, Adams F, Holmes VF, Levy JK, Neidhart M. Methylphenidate for depressive disorders in cancer patients. An alternative to standard antidepressants. Psychosomatics. 1987;28:455-461.
12. Woods SW, Tesar GE, Murray GB, Cassem NH. Psychostimulant treatment of depressive disorders secondary to medical illness. J Clin Psychiatry. 1986;47:12-15.
13. Llana ME, Crismon ML. Methylphenidate: increased abuse or appropriate use? J Am Pharm Assoc (Wash). 1999;39:526-530.
14. Weintraub M, Singh S, Byrne L, Maharaj K, Guttmacher L. Consequences of the 1989 New York state triplicate benzodiazepine prescription regulations. JAMA. 1991;266:2392-2397.
15. Benzodiazepines: additional effects of the triplicate program. N Y State J Med. 1990;90:273-275.
16. Schwartz HI. Negative clinical consequences of triplicate prescription regulation of benzodiazepines. N Y State J Med. 1991;91:9S-12S.
17. List of top 200 drugs includes a few surprises. Drug Topics. 1999;143:30-33.
18. Jaffe JH. Impact of scheduling on the practice of medicine and biomedical research. Drug Alcohol Depend. 1985;14:403-418.
19. Clark HW. Legal implications of prescribing opioid controlled substances. Am J Orthop. 1998;27:29-32.
20. Glass RM. Benzodiazepine prescription regulation. Autonomy and outcome [editorial]. JAMA. 1991;266:2431-2433.
21. Gittelman R, Kanner A. Psychopharmacotherapy. In: Quay H, Werry J, eds. Psychopathological Disorders of Childhood 3rd ed. New York, NY: John Wiley & Sons; 1986:455-494.
22. Berkovitch M, Pope E, Phillips J, Koren G. Pemoline-associated fulminant liver failure: testing the evidence for causation. Clin Pharmacol Ther. 1995;57:696-698.
23. Adcock KG, MacElroy DE, Wolford ET, Farrington EA. Pemoline therapy resulting in liver transplantation. Ann Pharmacother 1998;32:422-425.
24. Stevenson RD, Wolraich ML. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. Pediatr Clin North Am. 1989;36:1183-1197.
25. Clark HW. Policy and medical-legal issues in the prescribing of controlled substances. J Psychoactive Drugs. 1991;23:321-328.
26. Schiff GD, Rucker TD. Computerized prescribing. Building the electronic infrastructure for better medication usage. JAMA. 1998;279:1024-1029.
27. Masand PS, Anand VS, Tanquary JF. Psychostimulant augmentation of second generation antidepressants: a case series. Depress Anxiety. 1998;7:89-91.
28. Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med. 2001;161:411-420.
29. Olin J, Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics. 1996;37:57-62.